Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Urologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Patients undergoing open radical prostatectomy~Exclusion Criteria:~* Age \< 18 years~* Patients with drug eluting stent with a double antiplatelet therapy~* Atrial fibrillation~* Thrombophilic diathesis~* Allergy to tranexamic acid

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
- 2 (Type: PLACEBO_COMPARATOR): Patients belonging to the control group will receive the same volume of saline infusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).